Systemic Therapy for Advanced Solid Tumors: Lung, Bladder, and Head & Neck
This community focuses on the clinical management of advanced and metastatic solid tumors, specifically evaluating the efficacy of immunotherapy, targeted agents, and chemotherapy combinations in lung, bladder, and head and neck cancers.
The research is dominated by clinical trials and case studies involving non-small cell lung cancer, small cell lung cancer, and urothelial carcinoma. Recurring therapeutic strategies include immune checkpoint inhibitors (such as pembrolizumab and nivolumab), platinum-based chemotherapy, and targeted therapies for specific genetic mutations like EGFR. The work frequently addresses locally advanced disease, metastatic progression, and the integration of perioperative treatments. Key applications include first-line treatment protocols, management of platinum-resistant disease, and the combination of antibody-drug conjugates with immunotherapy. The literature heavily features squamous cell carcinoma and adenocarcinoma subtypes, with a strong emphasis on phase III trial outcomes and guideline-driven treatment algorithms for patients with advanced-stage disease.
The largest share of the community's output is found in platinum research, accounting for 3.2% of all platinum research, and 1,983 papers here. This is the element with the highest paper count within this group.
The community comprises 11,754 papers, primarily published in the Journal of Clinical Oncology, Frontiers in Oncology, and Cancers.
Recent work continues to focus on novel combinations for resistant disease, including osimertinib with chemotherapy for EGFR-mutated lung cancer and antibody-drug conjugates like disitamab vedotin for urothelial cancer. Other recent studies examine perioperative immunotherapy for bladder cancer and the mechanisms of resistance to PD-1 and CTLA-4 blockade.